The Latest Breaking News from FDA

The pharma industry is transforming due to the rapid adoption of AI and global healthcare spending, fostering innovation and patient care advancements. Therefore, fundamentally sound pharma stocks Eli Lilly (LLY), Wave Life Sciences (WVE) and Johnson & Johnson (JNJ) might be worth adding to boost your portfolio. Continue reading.

Backed by an ever-growing need for chronic disease treatments, rapid investments in research and development, and widespread integration of technology, the pharmaceutical sector is anticipated to flourish. Thus, as we approach the end of 2023, three solid pharma stocks, GoodRx Holdings (GDRX), CytomX Therapeutics (CTMX), and Neurocrine Biosciences (NBIX), could…

Donald Trump plans to skip testifying for a second time in the New York civil fraud trial. The FDA has approved the first-ever gene-editing treatment for a human disease.

Ministers are spending £290m of taxpayers’ money on a scheme that is yet to deliver. It’s our job as public servants to point out flaws in their plans, says Dave Penman, general secretary of the FDA union

From gonorrhea and syphilis to newer ailments, these are the STDs that you need to be on the watch for

Code found in the Fitbit app suggests that it might soon be able to work with the Pixel 8 Pro's built-in thermometer.

The U.S. Food and Drug Administration on Friday approved a pair of gene therapies for sickle cell disease, including the first treatment based on the breakthrough CRISPR gene editing technology.

The FDA approved two new therapies for sickle-cell disease, including the world's first-ever approved CRISPR therapy.

The announcement comes after the FDA became aware of more than 40 cases of "DRESS syndrome" linked to the seizure medications levetiracetam and clobazam.

The stock market rally enjoyed modest weekly gains, with the major indexes all near 2023 highs. AMD and Google surged on AI news.

The Food and Drug Administration approved two genetic treatments for sickle cell disease, including one that uses gene-editing. The approvals offer hope for patients and signal a new medical era.